Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 8/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | HCK | P08631 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4219847 | 0.91 | TLR7 (0.39) | TLR7TLR9TLR8ALDH1A1RXFP1 | |
| SCHEMBL4224372 | 0.84 | TLR9 (0.39) | TLR7TLR9TLR8ALDH1A1DHFR | |
| SCHEMBL4219502 | 0.84 | TLR7 (0.45) | TLR7TLR9TLR8ALDH1A1TSHR | |
| SCHEMBL4225661 | 0.83 | RECQL (0.44) | TLR7TLR9TLR8ALDH1A1ADORA1 | |
| SCHEMBL4046724 | 0.83 | TLR7 (0.48) | TLR7TLR9TLR8ADORA1PIK3CD | |
| SCHEMBL4226947 | 0.81 | LDHA (0.43) | TLR7TLR9TLR8 | |
| SCHEMBL4224839 | 0.80 | DHFR (0.47) | TLR7TLR9TLR8DHFRPIK3CD | |
| SCHEMBL4221482 | 0.80 | TLR7 (0.44) | TLR7TLR9TLR8 | |
| SCHEMBL4260417 | 0.78 | TLR7 (0.36) | TLR7TLR9TLR8DHFRGAA | |
| Trifluoroacetic Acid SCHEMBL4225684 | 0.77 | TLR7 (0.42) | TLR7TLR9TLR8TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303132-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | NOVARTIS AG (CH) | 2016-10-20 | — | — | US | claimed |
| US-20180125849-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | NOVARTIS AG (CH) | 2018-05-10 | — | — | US | disclosed |
| US-20160303132-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | NOVARTIS AG (CH) | 2016-10-20 | — | — | US | disclosed |
| US-8901134-B2 | Pyrazolo [3,4-D] pyrimidine derivatives useful to treat respiratory disorders | NOVARTIS AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-20140235632-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | NOVARTIS AG (CH) | 2014-08-21 | — | — | US | disclosed |
| US-20140051698-A1 | Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| US-20090131457-A1 | Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| EP-2026811-A1 | PYRAZOLO [3, 4-D]PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | Novartis AG (CH) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007134828-A1 | PYRAZOLO [3, 4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | NOVARTIS AG (CH) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131457-A1 | Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders | PIK3CA, JAK3, PDK1 | TLR7 1301/4885TLR9 1750/4885TLR8 2531/4885 |
| US-20140051698-A1 | Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders | PIK3CA, JAK3, PDK1 | TLR7 1301/4885TLR9 1750/4885TLR8 2531/4885 |
| US-20160303132-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | PIK3CA, JAK3, PDK1 | TLR7 1301/4885TLR9 1750/4885TLR8 2531/4885 |
| US-20140235632-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | PIK3CA, JAK3, PDK1 | TLR7 1301/4885TLR9 1750/4885TLR8 2531/4885 |
| US-20180125849-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | PIK3CA, JAK3, PDK1 | TLR7 1301/4885TLR9 1750/4885TLR8 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.